Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.510
-0.220 (-8.06%)
Aug 1, 2025, 4:00 PM - Market closed
CTI BioPharma Stock Forecast
ANVS's stock price has decreased by -73.04% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover CTI BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $18, which forecasts a 617.13% increase in the stock price over the next year. The lowest target is $12 and the highest is $25.
Price Target: $18.00 (+617.13%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jun 9, 2025.
Analyst Ratings
The average analyst rating for CTI BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $12 | Strong Buy | Maintains | $30 → $12 | +378.09% | Jun 9, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $26 → $17 | Strong Buy | Maintains | $26 → $17 | +577.29% | May 15, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Feb 10, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $21 | Strong Buy | Maintains | $21 | +736.65% | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +1,095.22% | Nov 11, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.63
from -2.31
EPS Next Year
-1.64
from -1.63
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.86 | -0.32 | -0.30 | ||
| Avg | -1.63 | -1.64 | -1.26 | ||
| Low | -2.46 | -2.72 | -1.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.